オプジーボ（ニボルマブ）の世界市場レポート2025年：疫学、パイプライン分析、市場インサイトと予測

オプジーボ（ニボルマブ）市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8%で112億8,160万米ドルに成長します。この予測期間における成長は、免疫療法の受容の拡大、免疫療法とその利点に対する理解の深まり、資本設備に対するヘルスケア支出の増加、様々な適応症に対するニボルマブの適用拡大、免疫療法治療に対する嗜好の高まりに起因すると考えられます。予測期間における主要動向としては、製品の技術革新、新規地域への市場拡大、進行中の臨床検査、個別化医療への傾向の高まり、がん研究の進歩などが挙げられます。

非小細胞肺がん（NSCLC）の有病率の上昇が、今後数年間のオプジーボ（ニボルマブ）市場の成長を牽引すると予測されています。NSCLCは肺がんの中で最も有病率が高く、肺がん全体の約85%を占めます。NSCLCの罹患率の増加は、主に喫煙、環境汚染物質への曝露、遺伝子変異、がんの家族歴などの要因に起因しています。オプジーボは、免疫細胞上のPD-1受容体を阻害することで機能し、がん細胞を識別して攻撃する身体の免疫反応を高めています。例えば、米国を拠点とする健康団体である米国がん協会によると、2024年に新たに診断された肺がん患者は23万4,580人で、その80％がNSCLCであり、肺がんと診断された23万8,340人であった2023年に比べて増加しています。したがって、非小細胞肺がんの罹患率の上昇がオプジーボ（ニボルマブ）市場の拡大を後押ししています。

オプジーボ（ニボルマブ）市場の重要な動向は、治療効果を高め、さまざまながん種での使用を拡大するための併用療法の開発です。これらの併用戦略は、耐性メカニズムに対処し、進行がん患者により包括的な治療選択肢を提供することを目的としています。例えば、米国食品医薬品局は2024年10月、切除可能なNSCLCを有する成人患者に対する術後補助療法として、ネオアジュバント治療としてプラチナ製剤二剤併用化学療法とそれに続くニボルマブ単剤療法をオプジーボ（ニボルマブ）として承認しました。今回の承認により、オプジーボは、EGFRまたはALKの変異が確認されていない患者に対して、手術前にプラチナ製剤2剤併用化学療法と併用し、手術後に単剤療法として使用することが可能となりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のオプジーボ（ニボルマブ）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のオプジーボ（ニボルマブ）市場：成長率分析
• 世界のオプジーボ（ニボルマブ）市場の実績：規模と成長、2019～2024年
• 世界のオプジーボ（ニボルマブ）市場の予測：規模と成長、2024～2029年、2034年
• 世界のオプジーボ（ニボルマブ）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のオプジーボ（ニボルマブ）市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 40mg/4mL
• 100mg/10mL
• 240mg/24mL
• 世界のオプジーボ（ニボルマブ）市場：投与別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射
• 溶液
• その他の投与
• 世界のオプジーボ（ニボルマブ）市場：人口統計別、実績と予測、2019～2024年、2024～2029年、2034年
• 成人
• 小児
• 世界のオプジーボ（ニボルマブ）市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 黒色腫
• 非小細胞肺がん（NSCLC）
• 悪性胸膜中皮腫
• 古典的ホジキンリンパ腫（CHL）
• 頭頸部扁平上皮がん（SCCHN）
• 腎細胞がん（RCC）
• その他
• 世界のオプジーボ（ニボルマブ）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• その他

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のオプジーボ（ニボルマブ）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のオプジーボ（ニボルマブ）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• オプジーボ（ニボルマブ）市場：競合情勢
• オプジーボ（ニボルマブ）市場：企業プロファイル
  • Bristol-Myers Squibb
  • Ono Pharmaceutical

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• オプジーボ（ニボルマブ）市場、2029年：新たな機会を提供する国
• オプジーボ（ニボルマブ）市場、2029年：新たな機会を提供するセグメント
• オプジーボ（ニボルマブ）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Opdivo (nivolumab) is a prescription medication classified as an immune checkpoint inhibitor, specifically targeting programmed death-1 (PD-1) receptors. It is a form of immunotherapy used to treat various types of cancer by enhancing the body's immune system to recognize and eliminate cancer cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary formulations available in the opdivo (nivolumab) market include 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml. The 40 mg/4 ml dosage is a lower concentration, intended for patients who need smaller doses, typically used in specific treatment protocols or for patients with lower body weight. These formulations are available in various forms, including injections and solutions, and are used across different age groups, including both adults and pediatric patients. Opdivo is applied in the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancers. The primary end-users of Opdivo are hospitals, clinics, and other healthcare settings.

The opdivo (nivolumab) market research report is one of a series of new reports from The Business Research Company that provides opdivo (nivolumab) market statistics, including opdivo (nivolumab) industry global market size, regional shares, competitors with a opdivo (nivolumab) market share, detailed opdivo (nivolumab) market segments, market trends, and opportunities, and any further data you may need to thrive in the opdivo (nivolumab) industry. This opdivo (nivolumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to $11,281.6 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growing acceptance of immunotherapy, enhanced understanding of immunotherapy and its benefits, growth in healthcare expenditure for capital equipment, increasing the application of nivolumab for various indications, and growing preference for immunotherapy treatments. Major trends in the forecast period include product innovation, expansion into new geographic markets, ongoing clinical trials, growing trend towards personalized medicine, and advancements in cancer research.

The rising prevalence of non-small cell lung cancer (NSCLC) is anticipated to drive the growth of the opdivo (nivolumab) market in the coming years. NSCLC is the most prevalent form of lung cancer, representing approximately 85% of all lung cancer cases. The growing incidence of NSCLC can mainly be attributed to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo functions by blocking the PD-1 receptor on immune cells, boosting the body's immune response to identify and attack cancer cells. For instance, in 2024, the American Cancer Society, a U.S.-based health organization, reported 234,580 new lung cancer cases diagnosed in the U.S., with 80% of those being NSCLC, showing an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Therefore, the rising incidence of non-small lung cancer is fueling the expansion of the opdivo (nivolumab) market.

A significant trend in the opdivo (nivolumab) market is the development of combination therapies to enhance treatment efficacy and broaden its use across various cancer types. These combination strategies aim to address resistance mechanisms and offer more comprehensive treatment alternatives for advanced cancer patients. For example, in October 2024, the U.S.-based Food and Drug Administration approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab post-surgery as adjuvant treatment for adults with resectable NSCLC. This approval allows Opdivo to be used in conjunction with platinum-doublet chemotherapy before surgery and as monotherapy afterward for patients without known EGFR or ALK mutations.

In November 2022, Lyvgen Biopharma, a biotech firm based in China, entered into a partnership with Bristol Myers Squibb (BMS). This collaboration aims to conduct a Phase II clinical trial assessing LVGN7409 in combination with Opdivo (nivolumab) for patients with advanced or metastatic NSCLC. Bristol Myers Squibb is the pharmaceutical company responsible for developing Opdivo (nivolumab).

Major players operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical.

North America was the largest region in the 0pdivo (nivolumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in opdivo (nivolumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the opdivo (nivolumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The opdivo (nivolumab) market consists of sales of monotherapy and combination therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Opdivo (nivolumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on opdivo (nivolumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for opdivo (nivolumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The opdivo (nivolumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL
• 2) By Dosage: Injection; Solution; Other Dosages
• 3) By Demographic: Adult; Pediatric
• 4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
• 5) By End-User: Hospitals; Clinics; Other End Users
• Companies Mentioned: Bristol-Myers Squibb; Ono Pharmaceutical
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Opdivo (Nivolumab) Market Characteristics

3. Opdivo (Nivolumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Opdivo (Nivolumab) Market Trends And Strategies

5. Opdivo (Nivolumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Opdivo (Nivolumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Opdivo (Nivolumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Opdivo (Nivolumab) Market Growth Rate Analysis
• 6.4. Global Opdivo (Nivolumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Opdivo (Nivolumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Opdivo (Nivolumab) Total Addressable Market (TAM)

7. Global Opdivo (Nivolumab) Market Pricing Analysis & Forecasts

8. Opdivo (Nivolumab) Market Segmentation

• 8.1. Global Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• >40 mg/4 mL
• 100 mg/10 mL
• 240 mg/24 mL
• 8.2. Global Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection
• Solution
• Other Dosages
• 8.3. Global Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Pediatric
• 8.4. Global Opdivo (Nivolumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Melanoma
• Non-small Cell Lung Cancer (NSCLC)
• Malignant Pleural Mesothelioma
• Classical Hodgkin Lymphoma (CHL)
• Squamous Cell Carcinoma of the Head and Neck (SCCHN)
• Renal Cell Carcinoma (RCC)
• Other Applications
• 8.5. Global Opdivo (Nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users

9. Global Opdivo (Nivolumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Opdivo (Nivolumab) Market Regional And Country Analysis

• 10.1. Global Opdivo (Nivolumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Opdivo (Nivolumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Opdivo (Nivolumab) Market

• 11.1. Asia-Pacific Opdivo (Nivolumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Opdivo (Nivolumab) Market

• 12.1. China Opdivo (Nivolumab) Market Overview
• 12.2. China Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Opdivo (Nivolumab) Market

• 13.1. India Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Opdivo (Nivolumab) Market

• 14.1. Japan Opdivo (Nivolumab) Market Overview
• 14.2. Japan Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Opdivo (Nivolumab) Market

• 15.1. Australia Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Opdivo (Nivolumab) Market

• 16.1. South Korea Opdivo (Nivolumab) Market Overview
• 16.2. South Korea Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Opdivo (Nivolumab) Market

• 17.1. Western Europe Opdivo (Nivolumab) Market Overview
• 17.2. Western Europe Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Opdivo (Nivolumab) Market

• 18.1. UK Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Opdivo (Nivolumab) Market

• 19.1. Germany Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Opdivo (Nivolumab) Market

• 20.1. France Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Opdivo (Nivolumab) Market

• 21.1. Eastern Europe Opdivo (Nivolumab) Market Overview
• 21.2. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Opdivo (Nivolumab) Market

• 22.1. North America Opdivo (Nivolumab) Market Overview
• 22.2. North America Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Opdivo (Nivolumab) Market

• 23.1. USA Opdivo (Nivolumab) Market Overview
• 23.2. USA Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Opdivo (Nivolumab) Market

• 24.1. Canada Opdivo (Nivolumab) Market Overview
• 24.2. Canada Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Opdivo (Nivolumab) Market

• 25.1. South America Opdivo (Nivolumab) Market Overview
• 25.2. South America Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Opdivo (Nivolumab) Market

• 26.1. Middle East Opdivo (Nivolumab) Market Overview
• 26.2. Middle East Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Opdivo (Nivolumab) Market

• 27.1. Africa Opdivo (Nivolumab) Market Overview
• 27.2. Africa Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Opdivo (Nivolumab) Market Competitive Landscape And Company Profiles

• 28.1. Opdivo (Nivolumab) Market Competitive Landscape
• 28.2. Opdivo (Nivolumab) Market Company Profiles
  • 28.2.1. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Ono Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis

29. Global Opdivo (Nivolumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Opdivo (Nivolumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Opdivo (Nivolumab) Market

32. Recent Developments In The Opdivo (Nivolumab) Market

33. Opdivo (Nivolumab) Market High Potential Countries, Segments and Strategies

• 33.1 Opdivo (Nivolumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Opdivo (Nivolumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Opdivo (Nivolumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer